Insider Buying: Dr. Martens (LON:DOCS) Insider Purchases 192 Shares of Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson bought 192 shares of the stock in a transaction dated Tuesday, January 13th. The shares were acquired at an average cost of GBX 78 per share, for a total transaction of £149.76.

Giles Wilson also recently made the following trade(s):

• On Thursday, December 11th, Giles Wilson purchased 197 shares of Dr. Martens stock. The stock was bought at an average price of GBX 76 per share, with a total value of £149.72.
• On Tuesday, November 11th, Giles Wilson purchased 176 shares of Dr. Martens stock. The shares were bought at an average cost of GBX 85 per share, for a total transaction of £149.60.

Dr. Martens Price Performance

Dr. Martens stock opened at GBX 75.15 on Thursday. The firm has a market cap of £726.37 million, a PE ratio of 44.21, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The stock’s fifty day moving average price is GBX 78.10 and its two-hundred day moving average price is GBX 83.50. Dr. Martens plc has a one year low of GBX 43.02 and a one year high of GBX 100.87.

Dr. Martens (LON:DOCS) last released its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. As a group, research analysts expect that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Peel Hunt reiterated a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 27th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 6,000.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.